|
IT1133025B
(it)
*
|
1979-06-29 |
1986-07-09 |
Wellcome Found |
Nuovi eteri per uso farmaceutico e procedimento per la loro preparazione
|
|
IL64573A
(en)
*
|
1980-12-18 |
1985-04-30 |
Wellcome Found |
Derivatives of formylphenoxyalkanoic acids and formylphenoxymethylbenzoic acids,their preparation and pharmaceutical formulations containing them
|
|
AU576322B2
(en)
|
1983-07-22 |
1988-08-25 |
Ici Australia Limited |
Alpha-substituted-alpha-cyanomethyl alcohols
|
|
US4783443A
(en)
|
1986-03-03 |
1988-11-08 |
The University Of Chicago |
Amino acyl cephalosporin derivatives
|
|
JPH05255106A
(ja)
|
1990-10-31 |
1993-10-05 |
Toray Ind Inc |
血小板減少症治療剤
|
|
JPH059164A
(ja)
|
1991-07-02 |
1993-01-19 |
Sumitomo Chem Co Ltd |
光学活性マンデロニトリル誘導体の製造方法
|
|
GB9217331D0
(en)
|
1992-08-14 |
1992-09-30 |
Xenova Ltd |
Pharmaceutical compounds
|
|
US6096786A
(en)
*
|
1992-10-01 |
2000-08-01 |
Glaxo Wellcome Inc. |
Immunopotentiatory agent and physiologically acceptable salts thereof
|
|
EP0609606B1
(en)
*
|
1992-10-01 |
1996-12-11 |
The Wellcome Foundation Limited |
Tucaresol as an immunopotentiatory agent
|
|
US5872151A
(en)
*
|
1992-10-01 |
1999-02-16 |
Glaxo Wellcome Inc. |
Immunopotentiatory agents and physiologically acceptable salts thereof
|
|
CA2149150C
(en)
|
1992-11-27 |
2000-08-01 |
David R. Carver |
Injectable taxol composition with improved stability
|
|
JPH0725858A
(ja)
|
1993-07-13 |
1995-01-27 |
Otsuka Pharmaceut Co Ltd |
ピペラジン誘導体
|
|
US5958980A
(en)
|
1993-08-26 |
1999-09-28 |
Glaxo Wellcome, Inc. |
Immunopotentiatory agent and physiologically acceptable salts thereof
|
|
IL110787A0
(en)
|
1993-08-27 |
1994-11-11 |
Sandoz Ag |
Biodegradable polymer, its preparation and pharmaceutical composition containing it
|
|
GB9402807D0
(en)
|
1994-02-14 |
1994-04-06 |
Xenova Ltd |
Pharmaceutical compounds
|
|
GB9402809D0
(en)
|
1994-02-14 |
1994-04-06 |
Xenova Ltd |
Pharmaceutical compounds
|
|
GB9426224D0
(en)
|
1994-12-23 |
1995-02-22 |
Xenova Ltd |
Pharmaceutical compounds
|
|
US5891877A
(en)
|
1995-02-14 |
1999-04-06 |
Xenova Limited |
Pharmaceutical compounds
|
|
US5874443A
(en)
|
1995-10-19 |
1999-02-23 |
Trega Biosciences, Inc. |
Isoquinoline derivatives and isoquinoline combinatorial libraries
|
|
US5886210A
(en)
|
1996-08-22 |
1999-03-23 |
Rohm And Haas Company |
Method for preparing aromatic compounds
|
|
JP3131574B2
(ja)
|
1996-09-04 |
2001-02-05 |
新日本製鐵株式会社 |
新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
|
|
US5939098A
(en)
|
1996-09-19 |
1999-08-17 |
Schering Corporation |
Cancer treatment with temozolomide
|
|
US5922683A
(en)
|
1997-05-29 |
1999-07-13 |
Abbott Laboratories |
Multicyclic erythromycin derivatives
|
|
AUPO735997A0
(en)
|
1997-06-17 |
1997-07-10 |
Fujisawa Pharmaceutical Co., Ltd. |
Piperazine derivatives
|
|
EP2201945B1
(en)
|
1997-11-21 |
2013-03-06 |
Purdue Neuroscience Company |
Use of substituted 2-aminoacetamides for treating or ameliorating anxiety
|
|
EP1051397B1
(en)
|
1998-01-29 |
2008-12-31 |
Aventis Pharmaceuticals Inc. |
Method for preparing an n- (aliphatic or aromatic)carbonyl -2-aminoacetamide compound and a cyclyzed compound
|
|
US7141603B2
(en)
|
1999-02-19 |
2006-11-28 |
The Regents Of The University California |
Antitumor agents
|
|
US6069146A
(en)
|
1998-03-25 |
2000-05-30 |
The Regents Of The University Of California |
Halimide, a cytotoxic marine natural product, and derivatives thereof
|
|
IL137974A0
(en)
|
1998-03-26 |
2001-10-31 |
Shionogi & Co |
Indole derivatives having antiviral activity
|
|
US6509331B1
(en)
|
1998-06-22 |
2003-01-21 |
Elan Pharmaceuticals, Inc. |
Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
|
|
GB9818627D0
(en)
|
1998-08-26 |
1998-10-21 |
Glaxo Group Ltd |
Improvements in dva vaccination
|
|
FR2784988B1
(fr)
|
1998-10-23 |
2002-09-20 |
Adir |
Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
US7026322B2
(en)
|
1998-11-12 |
2006-04-11 |
Nereus Pharmaceuticals, Inc. |
Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
|
|
US6358957B1
(en)
|
1998-11-12 |
2002-03-19 |
Nereus Pharmaceuticals, Inc. |
Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
|
|
MXPA02001878A
(es)
|
1999-08-23 |
2003-08-20 |
Dana Farber Cancer Inst Inc |
Moleculas b7-4 novedosas y usos de las mismas.
|
|
ES2539411T3
(es)
|
1999-08-23 |
2015-06-30 |
Dana-Farber Cancer Institute, Inc. |
PD-1, receptor para la B7-4 y su utilización
|
|
CA3016482A1
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
|
EP1264831A4
(en)
|
2000-01-18 |
2005-11-23 |
Nereus Pharmaceuticals Inc |
Cell division inhibitors and a method for fixing the same
|
|
JP2003528068A
(ja)
*
|
2000-03-17 |
2003-09-24 |
コリクサ コーポレイション |
新規両親媒性アルデヒドならびにアジュバントおよび免疫エフェクターとしてのそれらの使用
|
|
JP5101781B2
(ja)
|
2000-05-09 |
2012-12-19 |
アンギオアールエックス コーポレイション |
ピペラジンジオン化合物
|
|
WO2002064592A1
(en)
|
2000-12-28 |
2002-08-22 |
Neurocrine Biosciences, Inc. |
Tricyclic crf receptor antagonists
|
|
US20030082140A1
(en)
|
2001-08-20 |
2003-05-01 |
Fisher Paul B. |
Combinatorial methods for inducing cancer cell death
|
|
AU2003213673A1
(en)
|
2002-03-01 |
2003-09-16 |
Pintex Pharmaceuticals, Inc. |
Pin1-modulating compounds and methods of use thereof
|
|
NZ535992A
(en)
|
2002-05-17 |
2008-11-28 |
Aventis Pharma Sa |
Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
|
|
US7012100B1
(en)
|
2002-06-04 |
2006-03-14 |
Avolix Pharmaceuticals, Inc. |
Cell migration inhibiting compositions and methods and compositions for treating cancer
|
|
AU2003302721B2
(en)
|
2002-08-02 |
2009-10-08 |
Beyondspring Pharmaceuticals, Inc. |
Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
|
|
US7919497B2
(en)
|
2002-08-02 |
2011-04-05 |
Nereus Pharmaceuticals, Inc. |
Analogs of dehydrophenylahistins and their therapeutic use
|
|
US7935704B2
(en)
|
2003-08-01 |
2011-05-03 |
Nereus Pharmaceuticals, Inc. |
Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
|
|
SE0202429D0
(sv)
|
2002-08-14 |
2002-08-14 |
Astrazeneca Ab |
Novel Compounds
|
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
|
US20040197312A1
(en)
|
2003-04-02 |
2004-10-07 |
Marina Moskalenko |
Cytokine-expressing cellular vaccine combinations
|
|
BRPI0506655A
(pt)
|
2004-02-04 |
2007-05-08 |
Nereus Pharmaceuticals Inc |
dehidrofenilahistinas e seus análogos, e sìntese de dehidrofenilahistinas e seus análogos
|
|
EP1740593B1
(en)
|
2004-04-19 |
2016-04-06 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form i
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
WO2007035841A1
(en)
|
2005-09-21 |
2007-03-29 |
Nereus Pharmaceuticals, Inc. |
Analogs of dehydrophenylahistins and their therapeutic use
|
|
KR20080089489A
(ko)
|
2006-01-18 |
2008-10-06 |
메르크 파텐트 게엠베하 |
인테그린 리간드를 사용하는 암치료용 특이적 요법
|
|
WO2007113648A2
(en)
*
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Ctla4 antibody combination therapy
|
|
US8129527B2
(en)
|
2006-11-03 |
2012-03-06 |
Nereus Pharmacuticals, Inc. |
Analogs of dehydrophenylahistins and their therapeutic use
|
|
CN101657213B
(zh)
*
|
2007-02-15 |
2014-02-26 |
曼康公司 |
用于增强t细胞应答的方法
|
|
CN101678078B
(zh)
|
2007-04-13 |
2014-12-10 |
阿布拉西斯生物科学公司 |
Sparc及其使用方法
|
|
US20090170837A1
(en)
|
2007-08-17 |
2009-07-02 |
Thallion Pharmaceuticals Inc. |
Methods for treating ras driven cancer in a subject
|
|
US8569262B2
(en)
|
2007-11-02 |
2013-10-29 |
Momenta Pharmaceuticals, Inc. |
Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
|
|
US8449886B2
(en)
|
2008-01-08 |
2013-05-28 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
UY31952A
(es)
|
2008-07-02 |
2010-01-29 |
Astrazeneca Ab |
5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
BRPI1004940A2
(pt)
|
2009-01-16 |
2018-06-19 |
Teva Pharma |
composição farmacêutica
|
|
WO2010114922A1
(en)
|
2009-03-31 |
2010-10-07 |
Agios Pharmaceuticals, Inc. |
Methods of treating cancer having an aberrant egfr or kras genotype
|
|
GB0907551D0
(en)
|
2009-05-01 |
2009-06-10 |
Univ Dundee |
Treatment or prophylaxis of proliferative conditions
|
|
AU2010282744B2
(en)
|
2009-08-10 |
2014-08-28 |
Board Of Regents, The University Of Texas System |
Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent
|
|
EA201200486A1
(ru)
|
2009-09-15 |
2012-08-30 |
Серулин Фарма Инк. |
Лечение онкологических заболеваний
|
|
EP2490713A2
(en)
*
|
2009-10-23 |
2012-08-29 |
MannKind Corporation |
Cancer immunotherapy and method of treatment
|
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
|
CN101766815B
(zh)
|
2009-12-31 |
2012-04-25 |
胡松华 |
紫杉醇及多西紫杉醇的用途
|
|
EP2542699A4
(en)
|
2010-03-03 |
2013-10-02 |
Targeted Molecular Diagnostics Llc |
METHODS FOR DETERMINING REACTIVITY TO A MEDICINE BASED ON DETERMINATION OF RAS MUTATION AND / OR RAS AMPLIFICATION
|
|
US20130064831A1
(en)
|
2010-05-17 |
2013-03-14 |
Bristol-Myers Squibb Company |
Immunotherapeutic dosing regimens and combinations thereof
|
|
WO2011151423A1
(en)
|
2010-06-04 |
2011-12-08 |
Exonhit S.A. |
Substituted isoquinolines and their use as tubulin polymerization inhibitors
|
|
JP2012033526A
(ja)
|
2010-07-28 |
2012-02-16 |
Fuji Electric Co Ltd |
薄膜太陽電池およびその製造方法
|
|
WO2012035436A1
(en)
*
|
2010-09-15 |
2012-03-22 |
Tokyo University Of Pharmacy And Life Sciences |
Plinabulin prodrug analogs and therapeutic uses thereof
|
|
WO2012074904A2
(en)
|
2010-11-29 |
2012-06-07 |
Precision Therapeutics, Inc. |
Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
|
|
TWI386203B
(zh)
|
2011-01-07 |
2013-02-21 |
Univ China Medical |
治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
|
|
CA2833636A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
EP2786140A4
(en)
|
2011-11-28 |
2015-10-28 |
Nat Res Council Canada |
PACLITAXEL REACTION MARKERS FOR CANCER
|
|
WO2013090552A1
(en)
|
2011-12-13 |
2013-06-20 |
Yale University |
Compositions and methods for reducing ctl exhaustion
|
|
BR112014028094B1
(pt)
|
2012-05-09 |
2022-03-03 |
Cantex Pharmaceuticals, Inc |
Uso de um heparinoide interagindo com fator de plaqueta 4
|
|
AU2013204313C1
(en)
|
2012-06-01 |
2016-04-07 |
Bionomics Limited |
Combination Therapy
|
|
CA2889182A1
(en)
|
2012-10-26 |
2014-05-01 |
The University Of Chicago |
Synergistic combination of immunologic inhibitors for the treatment of cancer
|
|
SG11201505896YA
(en)
|
2013-02-20 |
2015-09-29 |
Novartis Ag |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
|
CA2905418C
(en)
|
2013-03-13 |
2023-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods for modulating chemotherapeutic cytotoxicity
|
|
EP2988668B1
(en)
|
2013-04-24 |
2019-07-24 |
Tel HaShomer Medical Research Infrastructure and Services Ltd. |
Magnetic resonance maps for analyzing tissue
|
|
AU2014276440A1
(en)
|
2013-06-03 |
2015-11-05 |
Novartis Ag |
Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a BRaf inhibitor
|
|
EP3076972B1
(en)
|
2013-10-11 |
2021-10-06 |
BeyondSpring, Inc. |
Cancer treatment with combination of plinabulin and taxane
|
|
EA201690912A1
(ru)
|
2013-11-05 |
2016-10-31 |
Когнейт Биосервисис, Инк. |
Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
|
|
ES2738289T3
(es)
|
2013-11-06 |
2020-01-21 |
Hospital Clinic Barcelona |
Procedimiento para el subtipado de tipos de linfoma por medio de perfiles de expresión
|
|
CN104796448B
(zh)
|
2014-01-22 |
2019-02-12 |
腾讯科技（深圳）有限公司 |
网络系统的数据处理方法和装置
|
|
US9850225B2
(en)
*
|
2014-04-14 |
2017-12-26 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
CN106794246B
(zh)
*
|
2014-08-08 |
2021-10-15 |
OncoQuest制药有限公司 |
肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
|
|
WO2016081281A1
(en)
|
2014-11-17 |
2016-05-26 |
Salk Institute For Biological Studies |
Lipophilic bisphosphonates and methods of use
|
|
MX394865B
(es)
|
2015-02-12 |
2025-03-24 |
Beyondspring Pharmaceuticals Inc |
Uso de plinabulina en combinación con inhibidores de punto de control inmunitario
|
|
WO2016144636A1
(en)
|
2015-03-06 |
2016-09-15 |
Beyondspring Pharmaceuticals, Inc. |
Method of treating a brain tumor
|
|
HK1249052A1
(zh)
|
2015-03-06 |
2018-10-26 |
BeyondSpring Pharmaceuticals Inc. |
治疗与ras突变相关的癌症的方法
|
|
WO2016165007A1
(en)
|
2015-04-17 |
2016-10-20 |
The University Of British Columbia |
Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer
|
|
CN106279039B
(zh)
|
2015-06-02 |
2019-01-11 |
青岛海洋生物医药研究院股份有限公司 |
氘代脱氢苯基阿夕斯丁类化合物及其制备方法和在制备抗肿瘤的药物中的应用
|
|
EP3334726B1
(en)
|
2015-07-13 |
2022-03-16 |
Beyondspring Pharmaceuticals, Inc. |
Plinabulin compositions
|
|
CA2996426A1
(en)
|
2015-10-05 |
2017-04-13 |
Cedars-Sinai Medical Center |
Method of classifying and diagnosing cancer
|
|
US10912748B2
(en)
*
|
2016-02-08 |
2021-02-09 |
Beyondspring Pharmaceuticals, Inc. |
Compositions containing tucaresol or its analogs
|
|
CN109475524A
(zh)
|
2016-06-06 |
2019-03-15 |
万春药业公司 |
用于减少中性粒细胞减少症的组合物和方法
|
|
WO2018129381A1
(en)
|
2017-01-06 |
2018-07-12 |
Beyondspring Pharmaceuticals, Inc. |
Tubulin binding compounds and therapeutic use thereof
|
|
KR20190109479A
(ko)
|
2017-02-01 |
2019-09-25 |
비욘드스프링 파마수티컬스, 인코포레이티드. |
호중구감소증의 감소 방법
|
|
BR112019018880A2
(pt)
|
2017-03-13 |
2020-04-14 |
Beyondspring Pharmaceuticals, Inc. |
composições de plinabulina e seu uso
|
|
WO2019126739A1
(en)
|
2017-12-21 |
2019-06-27 |
Shepherd Therapeutics, Inc. |
Pyrvinium pamoate anti-cancer therapies
|
|
WO2019147615A1
(en)
|
2018-01-24 |
2019-08-01 |
Beyondspring Pharmaceuticals, Inc. |
Composition and method for reducing thrombocytopenia via the administration of plinabulin
|
|
BR112020015758A2
(pt)
|
2018-02-01 |
2020-12-08 |
Beyondspring Pharmaceuticals, Inc. |
Composição e método para reduzir neutropenia induzida por quimioterapia através da administração de plinabulina e agente de g-csf
|
|
CN110240592A
(zh)
|
2018-03-08 |
2019-09-17 |
青岛海洋生物医药研究院股份有限公司 |
(z)-3-(3-甲酰基苯亚甲基)哌嗪二酮类化合物及其在制备抗肿瘤药物中的应用
|
|
CA3095709A1
(en)
|
2018-04-05 |
2019-10-10 |
Noviga Research Ab |
Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer
|
|
US20210161888A1
(en)
|
2018-06-01 |
2021-06-03 |
Beyondspring Pharmaceuticals, Inc. |
Composition and method of treating cancer associated with egfr mutation
|
|
KR20210047309A
(ko)
|
2018-08-16 |
2021-04-29 |
비욘드스프링 파마수티컬스, 인코포레이티드. |
면역 반응을 자극하기 위한 방법 및 조성물
|
|
AU2019378779A1
(en)
|
2018-11-14 |
2021-06-03 |
Beyondspring Pharmaceuticals, Inc. |
Methods of treating cancer using tubulin binding agents
|
|
CN112778155B
(zh)
|
2019-11-11 |
2023-08-11 |
大连万春布林医药有限公司 |
妥卡雷琐衍生物及其用途
|
|
KR20230006568A
(ko)
|
2020-05-04 |
2023-01-10 |
비욘드스프링 파마수티컬스, 인코포레이티드. |
낮은 면역원성을 갖는 암에서 암세포 사멸을 강화하기 위한 삼중 병용 요법
|